Dr. Helena Yu, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
18 drugs studied
Area of expertise
1Lung Cancer
Stage IV
EGFR positive
EGFR
2Non-Small Cell Lung Cancer
Stage IV
EGFR positive
Stage III
Affiliated Hospitals
Clinical Trials Helena Yu, MD is currently running
Osimertinib + Chemotherapy
for Lung Cancer
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
Recruiting1 award Phase 29 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Helena Yu, MD
Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Helena Yu, MD has experience with
- Osimertinib
- Carboplatin
- Pemetrexed
- Etoposide
- Platinum
- Amivantamab
Breakdown of trials Helena Yu, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Helena Yu, MD specialize in?
Helena Yu, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are EGFR positive.
Is Helena Yu, MD currently recruiting for clinical trials?
Yes, Helena Yu, MD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Helena Yu, MD has studied deeply?
Yes, Helena Yu, MD has studied treatments such as Osimertinib, Carboplatin, Pemetrexed.
What is the best way to schedule an appointment with Helena Yu, MD?
Apply for one of the trials that Helena Yu, MD is conducting.
What is the office address of Helena Yu, MD?
The office of Helena Yu, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.